WHO Ebola Vaccination Congo
- On September 14,2023,the Democratic Republic of Congo (DRC) initiated a new Ebola vaccination campaign utilizing a ring vaccination strategy,marking a significant step forward in controlling the spread of...
- It was first employed during the 1960s to eradicate smallpox and has since been adapted for ebola control.
- The first dose is administered with the Zabdeno vaccine, developed by Janssen pharmaceutical Companies of Johnson & Johnson, and the second dose with Mvabea, manufactured by Merck.
A New Era in Ebola Prevention: Ring Vaccination in the Democratic Republic of Congo
Table of Contents
On September 14,2023,the Democratic Republic of Congo (DRC) initiated a new Ebola vaccination campaign utilizing a ring vaccination strategy,marking a significant step forward in controlling the spread of the deadly virus.This approach, proven effective in previous outbreaks, focuses on vaccinating not only confirmed cases but also their contacts and contacts of contacts – forming a protective “ring” around the infection.
Understanding Ring Vaccination
Ring vaccination isn’t a new concept. It was first employed during the 1960s to eradicate smallpox and has since been adapted for ebola control. The strategy is especially valuable in resource-limited settings like the DRC, where widespread vaccination isn’t always feasible.By targeting those most at risk, it maximizes the impact of limited vaccine supplies.
The Vaccine Used: Zabdeno and Mvabea
The DRC’s current campaign utilizes a two-dose regimen. The first dose is administered with the Zabdeno vaccine, developed by Janssen pharmaceutical Companies of Johnson & Johnson, and the second dose with Mvabea, manufactured by Merck. Clinical trials have demonstrated the safety and efficacy of this combination, offering significant protection against the Ebola virus.
Historical Context: Past Outbreaks and Vaccination Efforts
The DRC has experienced numerous Ebola outbreaks, with the most recent declared over on May 3, 2023.Prior to this,a major outbreak in North Kivu and Ituri provinces,lasting from August 2018 to June 2020,saw over 3,400 cases and more than 2,200 deaths. The use of the rVSV-ZEBOV vaccine during that outbreak demonstrated its effectiveness in containing the virus, paving the way for the current ring vaccination strategy.
The World Health Organization (WHO) plays a crucial role in supporting the DRC’s Ebola response, providing technical guidance, vaccine supplies, and logistical support.
>
Challenges and Future Outlook
despite the success of ring vaccination, challenges remain. Reaching remote communities, addressing vaccine hesitancy fueled by misinformation, and maintaining a robust surveillance system are critical for sustained control. Ongoing research is also focused on developing more effective vaccines and therapeutics.
| Outbreak | Dates | Cases | Deaths |
|---|---|---|---|
| North Kivu/Ituri | Aug 2018 – Jun 2020 | 3,470 | 2,280 |
| Équateur Province | Jun – Nov 2020 | 130 | 55 |
As of September 15, 2025, the DRC continues to refine its Ebola prevention strategies, building on the lessons learned from past outbreaks and embracing innovative approaches like ring vaccination to protect its population. Continued international collaboration and investment in public health infrastructure are essential to prevent future epidemics.